Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Exercise / conversionDeferred Stock Units · Derivative | 4,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004922 · doc4.xml · derivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,472 Underlying: Common Stock · 4,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Tax withholdingCommon Stock | 1,546 | $24.81 | $38,356.26 |
DisclosureSEC source: 0001225208-17-004922 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,450 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Exercise / conversionCommon Stock | 4,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004922 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:45 UTC |
Ballinger Kevin J.SVP & Pres, Interven Cardio
|
Exercise / conversionDeferred Stock Units · Derivative | 3,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004920 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,185 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:45 UTC |
Ballinger Kevin J.SVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 1,071 | $24.81 | $26,571.51 |
DisclosureSEC source: 0001225208-17-004920 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,724 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:45 UTC |
Ballinger Kevin J.SVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 3,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004920 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · SVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:45 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 3,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004919 · doc4.xml · derivative · entry 2 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,185 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:45 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 3,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004919 · doc4.xml · nonDerivative · entry 1 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 21:28 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
Tax withholdingCommon Stock | 1,194 | $24.48 | $29,229.12 |
DisclosureSEC source: 0001225208-17-004574 · doc4.xml · nonDerivative · entry 2 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,105 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
Exercise / conversionDeferred Stock Units · Derivative | 4,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004765 · doc4.xml · derivative · entry 3 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,174 Underlying: Common Stock · 4,587 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
Tax withholdingCommon Stock | 1,489 | $24.78 | $36,897.42 |
DisclosureSEC source: 0001225208-17-004765 · doc4.xml · nonDerivative · entry 2 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,203 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
Exercise / conversionCommon Stock | 4,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004765 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionDeferred Stock Units · Derivative | 1,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004764 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 Underlying: Common Stock · 1,529 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Tax withholdingCommon Stock | 500 | $24.78 | $12,390.00 |
DisclosureSEC source: 0001225208-17-004764 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,568 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionCommon Stock | 1,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004764 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionDeferred Stock Units · Derivative | 1,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004763 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 Underlying: Common Stock · 1,529 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Tax withholdingCommon Stock | 337 | $24.78 | $8,350.86 |
DisclosureSEC source: 0001225208-17-004763 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,946.99 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:29 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionCommon Stock | 1,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004763 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,283.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:28 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 3,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004762 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,116 Underlying: Common Stock · 3,058 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:28 UTC |
Pierce David ASVP and President, Endoscopy
|
Tax withholdingCommon Stock | 993 | $24.78 | $24,606.54 |
DisclosureSEC source: 0001225208-17-004762 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,082 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 22:28 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionCommon Stock | 3,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004762 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:30 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionDeferred Stock Units · Derivative | 3,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004742 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,881 Underlying: Common Stock · 3,440 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:30 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Tax withholdingCommon Stock | 1,117 | $24.78 | $27,679.26 |
DisclosureSEC source: 0001225208-17-004742 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,561 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:30 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 3,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004742 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionDeferred Stock Units · Derivative | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004741 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,352 Underlying: Common Stock · 2,676 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Tax withholdingCommon Stock | 1,006 | $24.78 | $24,928.68 |
DisclosureSEC source: 0001225208-17-004741 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,291 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004741 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 2,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004740 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,970 Underlying: Common Stock · 2,485 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 835 | $24.78 | $20,691.30 |
DisclosureSEC source: 0001225208-17-004740 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,352 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004740 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 29,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004739 · doc4.xml · derivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,104 Underlying: Common Stock · 29,052 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 13,669 | $24.78 | $338,717.82 |
DisclosureSEC source: 0001225208-17-004739 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,642,090 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:29 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 29,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004739 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,655,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
Exercise / conversionDeferred Stock Units · Derivative | 4,778 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004738 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,557 Underlying: Common Stock · 4,778 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
Tax withholdingCommon Stock | 1,606 | $24.78 | $39,796.68 |
DisclosureSEC source: 0001225208-17-004738 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,223 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
Exercise / conversionCommon Stock | 4,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004738 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Exercise / conversionDeferred Stock Units · Derivative | 2,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004737 · doc4.xml · derivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,588 Underlying: Common Stock · 2,293 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Tax withholdingCommon Stock | 867 | $24.78 | $21,484.26 |
DisclosureSEC source: 0001225208-17-004737 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,219 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Dawkins Keith DEVP, Global Chief Med. Off.
|
Exercise / conversionCommon Stock | 2,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004737 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 2,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004735 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,970 Underlying: Common Stock · 2,485 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 807 | $24.78 | $19,997.46 |
DisclosureSEC source: 0001225208-17-004735 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,873 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 2,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004735 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 1,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004734 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676 Underlying: Common Stock · 1,338 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Tax withholdingCommon Stock | 666 | $24.78 | $16,503.48 |
DisclosureSEC source: 0001225208-17-004734 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,448 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionCommon Stock | 1,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004734 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionDeferred Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004733 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,468 Underlying: Common Stock · 5,734 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 2,160 | $24.78 | $53,524.80 |
DisclosureSEC source: 0001225208-17-004733 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,798 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004733 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004732 · doc4.xml · derivative · entry 2 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,352 Underlying: Common Stock · 2,676 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:27 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004732 · doc4.xml · nonDerivative · entry 1 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.